Skip to content

Sundy on promote the reconstruction of Inadequate responders in HIV/AIDS patients after combined antiretroviral therapy by Shen Ling Gu Ben granules

Sundy on promote the reconstruction of Inadequate responders in HIV/AIDS patients after combined antiretroviral therapy by Shen Ling Gu Ben granules

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015290
Enrollment
Unknown
Registered
2018-03-21
Start date
2018-05-01
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immune Deficiency Syndrome

Interventions

treatment group:Antiviral therapy of Western medicine combined with Shen Ling Gu Ben immune granules
control group:Antiviral therapy of Western medicine combined with Shen Ling Gu Ben immune granule

Sponsors

China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) the age of 18 years old -65 years, men and women are not limited; 2) HIV antibody positive was confirmed by Western Blot confirmatory test; 3) the time of receiving HAART was more than 1 years, and the plasma HIV load of 50copies/ml was greater than 18 months; 4) the count of CD4+T lymphocyte was less than 300 cells/ul, or increased less than 20% compared with the baseline of treatment; 5) in accordance with the spleen and kidney yang deficiency syndrome / lung spleen two deficiency syndrome diagnostic criteria.

Exclusion criteria

Exclusion criteria: In conformity with the inclusion criteria, one of the following conditions shall be excluded 1) severe opportunistic infection before the group was not controlled; 2) patients who enter the group in January or are participating in other drug clinical trials; 3) those who received immunomodulatory therapy within 1 months before the group were treated; 4) WBC < 2 * 10^9/L * 109/L, N < 1, Hb < 90g/L, PLT < 75 * 10^9/L, liver and kidney dysfunction (abnormal liver function refers to AST or ALT or T-BIL more than 2 times the upper limit of the reference value, abnormal renal function refers to creatinine clearance rate is lower than the normal value); 5) patients with hepatitis C, liver cirrhosis and syphilis; 6) pregnant women or breast-feeding women and women of childbearing age who have not adopted safe contraception measures.

Design outcomes

Primary

MeasureTime frame
Absolute value of CD4+ cells;Immune reconstruction efficiency;

Secondary

MeasureTime frame
Cell proliferation and apoptosis;Clinical symptoms;WHO quality of life scale;Viral load;

Countries

China

Contacts

Public ContactWang Jian

China Academy of Chinese Medical Sciences

62tiger@163.com+86 010-64039230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026